Non-Viral Sleeping Beauty Transposon Engineered CD19-CAR-NK Cells Show a Safe Genomic Integration Profile and High Antileukemic Efficiency

核转染 转座酶 生物 睡美人转座系统 CD19 白细胞介素21 嵌合抗原受体 白细胞介素12 分子生物学 细胞毒性T细胞 抗原 细胞培养 流式细胞术 转染 T细胞 CD8型 免疫学 转座因子 免疫系统 体外 基因 遗传学 基因组
作者
Tobias Bexte,Lacramioara Botezatu,Csaba Miskey,Julia Campe,Lisa Marie Reindl,Veronika Gebel,Winfried S. Wels,Michael Hudecek,Zoltán Ivics,Evelyn Ullrich
出处
期刊:Blood [Elsevier BV]
卷期号:138 (Supplement 1): 2797-2797 被引量:12
标识
DOI:10.1182/blood-2021-153999
摘要

Abstract Background: Natural Killer (NK) cells are known for their high intrinsic cytotoxic capacity. Recently, we and others showed that virally transduced NK cells equipped with a synthetic chimeric antigen receptor (CAR) targeting CD19 induced enhanced killing of acute lymphoblastic leukemia (ALL) cells. Here, we demonstrate for the first time that primary NK cells can be engineered using the non-viral Sleeping Beauty (SB) transposon/transposase system to stably express a CD19-CAR with a safe genomic integration profile and high anti-leukemic efficiency in vitro and in vivo. Methods: Primary NK cells were isolated from PBMCs from healthy donors. SB transposons vectorized as minicircles (MC), which encode either a Venus fluorescent protein or a CD19-CAR together with truncated EGFR (tEGFR) as a marker, were introduced in combination with the hyperactive SB100X transposase into primary NK cells via nucleofection. The genetically engineered NK cells were expanded using IL-15 cytokine stimulation under feeder-cell free conditions. Vector integration sites were mapped by analyzing the genomic region around each insertion site in genomic DNA from long-term cultivated gene-modified NK cells, engineered ether by lentiviral (LV) or SB-based technology. Stable gene delivery and biological activity were monitored by flow cytometry and cytotoxicity of CD19-CAR NK cells against CD19-positive ALL and CD19-negative cell lines. Results: Applying a protocol optimized with respect to nucleofection pulses, time points and plasmid ratios, primary NK cells showed long-lasting Venus expression (up to 50%) upon SB-mediated gene delivery with similar viability as non-treated (NT) NK cells during feeder-cell free ex-vivo expansion using IL-15. Likewise, SB transposon-engineered CD19-CAR NK cells displayed high viability, durable transgene expression (Fig 1 A), and no significant change in the NK cell phenotype profile. Next, we assessed vector integration into genomic safe harbors (GSH). GSH are defined as regions of human chromosomes that fulfill the following five criteria: not ultraconserved, >300 kb away from miRNA genes, >50 kb away from transcriptional start sites (TSS), >300 kb away from genes involved in cancer and outside transcription units. CD19-CAR NK cells generated using SB100X showed a significantly higher frequency of vector integration into GSH compared to LV-transduced CAR-NK cells and a significantly more-close to random nucleotide frequency (computer-generated random positions in the genome map to GSHs; random 43.68%; LV 14.78%, SB100X 23.99%; p<0.05) (Fig 1 B). MC.CD19-CAR NK cells generated with the SB platform demonstrated significantly higher cytotoxicity compared to NT NK cells against CD19-positive Sup-B15 ALL cells after long-term cultivation for two to three weeks and no loss of natural intrinsic cytotoxicity. After 4-hour co-culture, significantly enhanced specific tumor cell lysis was found for MC.CD19-CAR NK cells vs NT NK cells at all effector to target cell ratios (E:T) tested (E:T 20:1 83.88% vs 43.13%; E:T 10:1 75.18% vs 31.32%; E:T 5:1 67.38 vs 32.22%; E:T 1:1 42.54 vs 10.19%; p<0.05) (Fig 1 C). With regard to intrinsic natural cytotoxicity of NK cells, no significant decrease in cell killing was overserved for SB-gene-modified CD19-CAR NK cells compared to NT NK cells against CD19-negative K562 cells (E:T 5:1 83%; p<0.05) (Fig 1 D). Significantly enhanced antitumor potential of SB-generated CD19-CAR NK cells was confirmed in a systemic CD19-positive lymphoma xenograft model (NSG-Nalm-6/Luc) in vivo. After injection of 0.5x10 6 tumor cells per mouse and lymphoma engraftment, animals were treated with a single dose of 10x10 6 SB-modified CD19-CAR NK cells pooled from three different donors with a mean tEGFR/CAR expression of 34%. MC.CD19-CAR NK cell therapy resulted in rapid lymphoma eradication in all treated mice (n=4; p<0.05), whereas mice receiving similar amounts of NT NK cells showed progressive lymphoma growth comparable to untreated control mice (Fig 1 E-F). Conclusion: Taken together, the Sleeping Beauty transposon system represents an innovative gene therapy approach for non-viral engineering of safe, highly functional and relatively cost-efficient CAR-NK cells that may not only be suitable for ALL therapy but also for a broad range of other applications in cancer therapy. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
ly完成签到,获得积分10
刚刚
1秒前
AKTAO发布了新的文献求助10
2秒前
wwwww发布了新的文献求助20
3秒前
3秒前
Echo发布了新的文献求助10
3秒前
4秒前
lizh187完成签到 ,获得积分10
5秒前
JasonChan完成签到 ,获得积分10
5秒前
5秒前
Jasper的应助被oo采纳,获得30
6秒前
英姑的应助被辰侑依采纳,获得10
6秒前
我我发布了新的文献求助10
6秒前
6秒前
7秒前
天天发布了新的文献求助10
7秒前
Owen的应助被温凛采纳,获得10
7秒前
强强发布了新的文献求助10
8秒前
8秒前
8秒前
袁rrrr完成签到,获得积分10
8秒前
ww完成签到,获得积分10
8秒前
8秒前
AAA麻精批发完成签到,获得积分10
9秒前
10秒前
巴拉巴拉发布了新的文献求助10
11秒前
111发布了新的文献求助30
11秒前
11秒前
悦耳的城发布了新的文献求助10
12秒前
花青素ii发布了新的文献求助10
12秒前
英姑的应助被李峥采纳,获得10
13秒前
kychao完成签到,获得积分10
14秒前
liugm发布了新的文献求助10
14秒前
14秒前
幻文悠发布了新的文献求助10
14秒前
英俊的铭的应助被快乐的忆安采纳,获得20
14秒前
找回自己发布了新的文献求助10
15秒前
15秒前
科研通AI2S的应助被yxxxxx采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193684
求助须知:如何正确求助?哪些是违规求助? 9579855
关于积分的说明 21867890
捐赠科研通 7793357
什么是DOI,文献DOI怎么找? 3437385
关于科研通互助平台的介绍 2560783
邀请新用户注册赠送积分活动 2484193